Related Experiment Video

Updated: Mar 13, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES

Jeremy Chataway1

  • 1Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 13, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

11.0K

Related Experiment Videos

Last Updated: Mar 13, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

11.0K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K

Articles linked to this work by shared authors, journal, and citation graph.

Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.

Neurology·2026

B-cell repopulation and postpartum MS disease activity following ofatumumab cessation for pregnancy in women with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.

Brain communications·2026

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026

The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.

Journal of neurology·2026

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026

Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Who declines neurocognitive testing? A cross-sectional study in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Survivor bias and disease progression in observational cohorts in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

How well do junior neurology residents recognize multiple sclerosis? Analysis of the "Close the Loop" resident clinical acumen project.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Calreticulin and myeloproliferative neoplasms: linking biology to targeted therapies.

Expert review of clinical immunology·2026

Plant cytokinin ortho-topolin riboside suppresses the proliferation of multiple myeloma cells by promoting β-catenin degradation.

BMB reports·2026

MZF1 Inhibits TGFβ-1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

TRPM4 promotes ErSO-mediated oncosis-like cell death in prostate cancer cells.

Cancer research communications·2026

NEK2 Promotes OSCC Invasion and Metastasis by Activating TNF-α Signaling Through Impairment of Desmosomal Adhesion.

BioFactors (Oxford, England)·2026

Epigenetic modulation of NKG2D ligands enhances NKG2D-CAR T cell efficacy in neuroblastoma.

Journal of translational medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us